Key statistics
On Friday, Crescent Biopharma Inc (CBIO:NAQ) closed at 12.07, 38.42% above the 52 week low of 8.72 set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 11.23 |
|---|---|
| High | 12.43 |
| Low | 11.00 |
| Bid | 11.75 |
| Offer | 14.50 |
| Previous close | 11.33 |
| Average volume | 126.82k |
|---|---|
| Shares outstanding | 27.56m |
| Free float | 25.95m |
| P/E (TTM) | -- |
| Market cap | 312.22m USD |
| EPS (TTM) | -15.11 USD |
Data delayed at least 15 minutes, as of Mar 06 2026 21:00 GMT.
More ▼
- Crescent Biopharma Announces Grants of Inducement Awards
- Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- Crescent Biopharma to Present at March Investor Conferences
- Crescent Biopharma Announces Grants of Inducement Awards
- Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
- Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Crescent Biopharma Announces Grants of Inducement Awards
- Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
- Crescent Biopharma Announces Grants of Inducement Awards
- Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
More ▼
